Evaluating the Nasal Allergen Provocation Test for Allergen Immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive database of patients starting allergen immunotherapy (AIT) for allergic rhinitis. Participants will undergo a nasal allergen provocation test (NAPT) before, during, and after AIT to assess the treatment's cost-effectiveness and efficacy. The study involves four visits and two annual telephone contacts over three years, conducted at two hospitals specializing in ENT and Allergology. The goal is to monitor patient responses and improve treatment strategies for allergic rhinitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 and ≤60 years
* Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and/of immunocap for the specific IgEs.

OR suspected local allergic rhinitis

* Patients who start with AIT treatment
* The patient must be motivated and willing to come to all visits
* The patient must be able to understand and sign the informed consent

Exclusion Criteria:

* Uncontrolled asthma
* Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)
* Use of β-blockers, immunosuppressants or ACE inhibitors
* Hypersensitivity to aluminum hydroxide and/or hypersensitivity to any of the excipients in AIT
* Anaphylaxis after allergen challenge in the past
* Acute rhinosinusitis in the last 12 weeks
* Recent surgery on the nose and/or paranasal sinuses in the last 12 weeks
* Pregnancy

Where it's running

• UZ Leuven
  Leuven, Vlaam Brabant, Belgium Recruiting
• AZ Sint-Jan
  Bruges, Belgium Not yet recruiting

Study contacts

• Study coordinator: Margot Vandekerckhove
• Email: margot.vandekerckhove@uzleuven.be
• Phone: +3216332342

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rupatifen Fumarate Capsules for Seasonal Allergic Rhinitis

  This Phase 3 trial tests Rupatifen Fumarate Capsules in adults with seasonal allergic rhinitis to see if they reduce symptoms compared with Rupatadine Fumarate and placebo.

  Recruiting at 18 sites Phase 3 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Baoding, Hebei and 17 other locations · NCT07711262

• TQH2722 injection plus regular allergy treatment for seasonal pollen allergy

  This trial will test whether adding TQH2722 injections to usual care helps adults (18–75) with seasonal allergic rhinitis who had poor symptom control during pollen season.

  Recruiting at 3 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 29 other locations · NCT07398859

• Creating a risk assessment tool for thunderstorm asthma (CARISTA)

  This project will test whether lung tests, allergy blood markers and daily symptom tracking can predict which adults with hay fever in South‑Eastern Australia will have seasonal or thunderstorm-related asthma attacks over two spring seasons.

  Recruiting at 6 sites University of Melbourne · Albury, New South Wales and 5 other locations · NCT07055542

• Treatment of seasonal allergic rhinitis with MG-K10 monoclonal antibody injection

  This study is testing if an injection of a new medicine called MG-K10 can help people with seasonal allergies feel better compared to a placebo.

  Recruiting Phase 2/3 Shanghai Mabgeek Biotech.Co.Ltd · Beijing, Beijing Municipality · NCT06846385

• CM310 for uncontrolled seasonal allergic rhinitis

  This trial will try CM310, a medicine that blocks the interleukin‑4 receptor, in people whose seasonal allergic rhinitis is not well controlled by current treatments.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06300203

• Acupuncture for treating seasonal allergies

  This study is testing whether acupuncture can help people with moderate-to-severe seasonal allergies feel better compared to a placebo treatment and standard medication.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing · NCT04815668

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.